Literature DB >> 33536241

SGLT2 Inhibitors in Diabetic Kidney Disease.

Sophia Zoungas1, Ian H de Boer2.   

Abstract

Entities:  

Keywords:  diabetes; diabetic kidney disease; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2021        PMID： 33536241      PMCID： PMC8092054          DOI： 10.2215/CJN.18881220

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Authors:  Bettina J Kraus; Matthew R Weir; George L Bakris; Michaela Mattheus; David Z I Cherney; Naveed Sattar; Hiddo J L Heerspink; Ivana Ritter; Maximilian von Eynatten; Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Audrey Koitka-Weber
Journal:  Kidney Int       Date:  2020-11-10       Impact factor: 10.612

2.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

3.  Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.

Authors:  Janani Rangaswami; Vivek Bhalla; Ian H de Boer; Alexander Staruschenko; Johanna A Sharp; Radhika Rajgopal Singh; Kevin Bryan Lo; Katherine Tuttle; Muthiah Vaduganathan; Hector Ventura; Peter A McCullough
Journal:  Circulation       Date:  2020-09-28       Impact factor: 29.690

4.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal:  Lancet Diabetes Endocrinol       Date:  2019-09-05       Impact factor: 32.069

5.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

6.  Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

Authors:  Megumi Oshima; Meg J Jardine; Rajiv Agarwal; George Bakris; Christopher P Cannon; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Soo Kun Lim; Kenneth W Mahaffey; Bruce Neal; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Vlado Perkovic; Hiddo J L Heerspink
Journal:  Kidney Int       Date:  2020-12-11       Impact factor: 10.612

7.  Gaps and barriers in health-care provision for co-morbid diabetes and chronic kidney disease: a cross-sectional study.

Authors:  C Lo; H Teede; G Fulcher; M Gallagher; P G Kerr; S Ranasinha; G Russell; R Walker; S Zoungas
Journal:  BMC Nephrol       Date:  2017-02-28       Impact factor: 2.388

8.  Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.

Authors:  Fang-Hong Shi; Hao Li; Long Shen; Zhen Zhang; Yi-Hong Jiang; Yao-Min Hu; Xiao-Yan Liu; Zhi-Chun Gu; Jing Ma; Hou-Wen Lin
Journal:  Front Pharmacol       Date:  2019-09-19       Impact factor: 5.810

9.  Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.

Authors:  George Bakris; Megumi Oshima; Kenneth W Mahaffey; Rajiv Agarwal; Christopher P Cannon; George Capuano; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Hiddo J L Heerspink; Adeera Levin; Bruce Neal; Richard Oh; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Meg J Jardine; Vlado Perkovic
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-19       Impact factor: 8.237
  9 in total
  3 in total

Review 1.  Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.

Authors:  Marc Evans; Angharad R Morgan; Stephen C Bain; Sarah Davies; Umesh Dashora; Smeeta Sinha; Samuel Seidu; Dipesh C Patel; Hannah Beba; W David Strain
Journal:  Diabetes Ther       Date:  2022-03-29       Impact factor: 3.595

2.  Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis.

Authors:  Lauren Fusfeld; Jessica T Murphy; YooJin Yoon; Li Ying Kam; Kirsten E Peters; Pearl Lin Tan; Michael Shanik; Alexander Turchin
Journal:  PLoS One       Date:  2022-08-01       Impact factor: 3.752

Review 3.  Transforming the Care of Patients with Diabetic Kidney Disease.

Authors:  Frank C Brosius; David Cherney; Patrick O Gee; Raymond C Harris; Alan S Kliger; Katherine R Tuttle; Susan E Quaggin
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-08       Impact factor: 10.614
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.